At a glance
ClinicalIndex Comparison RecordN/ACompleted· 109 enrolled
Drug / intervention
Rosmalip® +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot, Randomized, Double Blind, Placebo Controlled Study to Evaluate an Immune System Modulator Nutritional Supplement for the Prevention of Infections in Cancer Patients Receiving Oncologic Treatment During the COVID-19 Pandemia.
Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares·interventional·Posted Oct 18, 2021·Updated Sep 21, 2023
In Brief
A clinical study evaluating Rosmalip® and Placebo for Infections and 2 related conditions. Completed, enrolled 109 participants across 1 site.
Detailed Summary
This study is designed to assess the safety and efficacy of Rosmalip® nutritional supplement compared to placebo in subjects with solid cancer for the prevention of infections including COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Covid19, Cancer
CountriesSpain
CollaboratorsIMDEA Food, Universidad Autonoma de Madrid
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartOct 2020
First PostedOct 2021
Primary CompletionSep 2022
Study CompletionDec 2022
TodayJul 2026
First PostedOct 18, 2021
Enrollment StartOct 28, 2020
Primary CompletionSep 30, 2022
Study CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.7 years ago
Interventions
Rosmalip®dietary
Nutritional Supplement+Usual Care
Placeboother
Placebo+Usual Care